
Dosimetric evaluation of incidental irradiation to the axilla during whole breast radiotherapy for patients with left-sided early breast cancer in the IMRT era
Author(s) -
Jayoung Lee,
Shin-Wook Kim,
Seung Hyun Son
Publication year - 2016
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000004036
Subject(s) - medicine , axilla , breast cancer , radiation therapy , nuclear medicine , radiology , cancer
The purpose of this study was to compare the dosimetric parameters for incidental irradiation to the axilla during whole breast radiotherapy (WBRT) with 3-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT). Twenty left breast cancer patients treated with WBRT after breast-conserving surgery (BCS) were enrolled in this study. Remnant breast tissue, 3 levels of the axilla, heart, and lung were delineated. We used 2 different radiotherapy methods: 3D-CRT with field-in-field technique and 7-field fixed-beam IMRT. The target coverage of IMRT was significantly better than that of 3D-CRT ( D mean : 49.72 ± 0.64 Gy vs 50.24 ± 0.66 Gy, P < 0.001; V 45 : 93.19 ± 1.40% vs 98.59 ± 0.30%, P < 0.001; V 47.5 : 86.43 ± 2.72% vs 95.00 ± 0.02%, P < 0.001, for 3D-CRT and IMRT, respectively). In the IMRT plan, a lower dose was delivered to a wider region of the heart and lung. Significantly lower axillary irradiation was shown throughout each level of axilla by IMRT compared to 3D-CRT ( D mean for level I: 42.58 ± 5.31 Gy vs 14.49 ± 6.91 Gy, P < 0.001; D mean for level II: 26.25 ± 10.43 Gy vs 3.41 ± 3.11 Gy, P < 0.001; D mean for level III: 6.26 ± 4.69 Gy vs 1.16 ± 0.51 Gy, P < 0.001; D mean for total axilla: 33.9 ± 6.89 Gy vs 9.96 ± 5.21 Gy, P < 0.001, for 3D-CRT and IMRT, respectively). In conclusion, the incidental dose delivered to the axilla was significantly lower for IMRT compared to 3D-CRT. Therefore, IMRT, which only includes the breast parenchyma, should be cautiously used in patients with limited positive sentinel lymph nodes and who do not undergo complete axillary lymph node dissection.